Clinical use of neuroleptic plasma levels

LDR 01147nam a2200313 a 4500
001 002714490
003 MiAaHDL
005 20210817000000.0
006 m d
007 cr bn ---auaua
008 931019s1993 dcua b 001 0 eng c
010 ⊔ ⊔ ‡a93016126
020 ⊔ ⊔ ‡a0880485248
035 ⊔ ⊔ ‡a(MiU)990027144900106381
035 ⊔ ⊔ ‡asdr-miu.990027144900106381
035 ⊔ ⊔ ‡a(OCoLC)27384621
035 ⊔ ⊔ ‡z(MiU)Aleph002714490
040 ⊔ ⊔ ‡aDNLM/DLC ‡cDLC ‡dNLM ‡dEYM
050 0 0 ‡aRM333.5 ‡b.C45 1993
060 0 ⊔ ‡aQV 77.9 ‡bC641 1993
082 0 0 ‡a616.89/18 ‡220
245 0 0 ‡aClinical use of neuroleptic plasma levels / ‡cedited by Stephen R. Marder, John M. Davis, and Philip G. Janicak.
260 ⊔ ⊔ ‡aWashington, DC : ‡bAmerican Psychiatric Press, ‡cc1993.
300 ⊔ ⊔ ‡axii, 152 p. : ‡bill. ; ‡c24 cm.
504 ⊔ ⊔ ‡aIncludes bibliographical references (p. 142) and index.
538 ⊔ ⊔ ‡aMode of access: Internet.
650 ⊔ 2 ‡aAnti-Anxiety Agents ‡xtherapeutic use.
650 ⊔ 2 ‡aAntipsychotic Agents ‡xblood.
650 ⊔ 0 ‡aBlood ‡xAnalysis.
650 ⊔ 0 ‡aAntipsychotic drugs ‡xDose-response relationship.
650 ⊔ 0 ‡aAntipsychotic drugs ‡xPharmacokinetics.
700 1 ⊔ ‡aJanicak, Philip G.
700 1 ⊔ ‡aDavis, John M. ‡q(John Marcell), ‡d1933-
700 1 ⊔ ‡aMarder, Stephen R., ‡d1945-
CID ⊔ ⊔ ‡a002714490
DAT 0 ⊔ ‡a19941118000000.0 ‡b20210817000000.0
DAT 1 ⊔ ‡a20210911090737.0 ‡b2024-02-28T18:47:27Z
DAT 2 ⊔ ‡a2024-02-28T18:30:02Z
CAT ⊔ ⊔ ‡aSDR-MIU ‡dALMA ‡lprepare.pl-004-008
FMT ⊔ ⊔ ‡aBK
HOL ⊔ ⊔ ‡0sdr-miu.990027144900106381 ‡aMiU ‡bSDR ‡cMIU ‡pmdp.39015029855866 ‡sMIU ‡1990027144900106381
974 ⊔ ⊔ ‡bMIU ‡cMIU ‡d20240228 ‡sgoogle ‡umdp.39015029855866 ‡y1993 ‡ric ‡qbib ‡tUS bib date1 >= 1930